96 results about "Stem cell marker" patented technology

The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and / or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and / or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and / or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic / stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.

A method of increasing the relative number of cells expressing one or more stem cell markers in a cell population including committed cells is described. The method comprises: i. contacting the cell population with an agent that operably engages said committed cells; and ii. incubating committed cells that are engaged by said agent such that the relative number of cells expressing one or more stem cell markers increases as a result of said engaging.

A method of increasing the relative number of cells expressing one or more stem cell markers in a cell population including committed cells is described. The method comprises: i. contacting the cell population with an agent that operably engages said committed cells; and ii. incubating committed cells that are engaged by said agent such that the relative number of cells expressing one or more stem cell markers increases as a result of said engaging.

Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.

The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the HMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.

The invention provides an isolated tissue comprising a source of millions of postnatal stem cells expressing embryonic stem cell markers, and a method of storing or banking such isolated tissue to provide stems cells for later therapeutic use for the donor or for allogeneic transplant with donor permission.

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

The invention belongs to the field of cytobiology and neurobiology, and provides an establishment method and application of a clinical-grade neural stem cell line. The method under GMP (Good Manufacturing Practice) control comprises two steps, namely, primary culturing of neural stem cells, and subculturing of neural stem cells. The identification result shows that the neural stem cell line established by the method can express a plurality of stem cell markers, can be differentiated into nerve cells, astrocyte and oligodendrocyte, has high stability, and is suitable for long-term culturing; a large amount of sufficient clinical-grade neural stem cells can be obtained by the method. The method can be used for establishing the neural stem cell line based on a plurality of neural stem cells and even single neural stem cell, and thus the error in study can be reduced as far as possible. By adopting the neural stem cell line established by the method and the cells obtained by differentiating the neural stem cell line, the problems of the safety and effectiveness risk in cell therapy of nervous system disease can be solved effectively, and safe and effective treatment on such diseases becomes possible.

A set of markers for melanoma cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression CD271.

A method for enriching a population of somatic mammary stem cells or mammary tumor stem cells based on low-density lipoprotein receptor-related protein 6 (LRP6). Also included are methods for screening for LRP6 modulators, as well as methods for reducing Wnt signaling, for treating Wnt signaling-related diseases, for detecting mammary basal-like cells, for diagnosing basal-like breast cancer, and for inhibiting proliferation of a tumor expressing LRP6, and compositions thereof.

It is disclosed here that low density lipoprotein receptor-related protein 5 (LRP5) is a cell surface marker for somatic mammary stem cells and mammary tumor stem cells. The disclosure here provides new tools for enriching somatic mammary stem cells and mammary tumor stem cells. Methods of screening for agents that modulate LRP5 activity, of treating mammary tumor or breast cancer, of monitoring somatic mammary stem cells and mammary tumor stem cells in vivo are also provided, and of assessing prognosis of human breast cancer.

The invention provides establishment and application of a hepatocellular carcinoma cell line HCC-LY10. Specifically, the hepatocellular carcinoma cell line HCC-LY10 provided in the invention has stable traits, can be subcultured stably and repeatedly, and is applicable to established animal models of hepatocellular carcinoma, thus being an ideal cell line for the basic and preclinical phase application study of hepatocellular carcinoma. In addition, the hepatocellular carcinoma cell line HCC-LY10 partially expresses hepatocellular carcinoma stem cell marker EpCAM. The invention also provides application of the cell line in establishing model animals, screening drugs, and other aspects.

The present invention is directed to unique properties of stem cells, including methods to identify stem cell markers by identifying molecules associated specifically with chromosomes in stem cells. More particularly, we have discovered that somatic stem cells repeatedly inherit an entire complement of chromosomes that contain the same parental template DNA strands from one generation to the next. The present invention also provides methods related to diagnosis, prognosis, and treatments for cancer and aging in mammalian tissus, including human.

The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting / transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected / transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.

The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the HMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.

The present invention relates to a medium composition for transforming stem cells from an aged person into young stem cells, and more particularly to a medium composition for culturing stem cells, which is used to rejuvenate stem cells from an aged person so as to have characteristics similar to those of the stem cells of young people, and to a method for rejuvenating stem cells, which comprises culturing stem cells from an aged person in the medium composition. According to the present invention, even mesenchymal stem cells collected from over 60 years old patients can be transformed into young mesenchymal stem cells having high differentiation ability, high telomerase activity, and high ability to express stem cell markers. Thus, the present invention can significantly increase the efficacy of cell therapy employing mesenchymal stem cells.

The present invention pertains to therapeutic methods which are based on the use of an agent specifically binding a tumor-associated carbohydrate antigen for the treatment of cancer stem cells and related diseases. Also provided are diagnostic and prognostic methods using a tumor- associated carbohydrate antigen as marker for cancer stem cells.

The present invention is directed to methods of treating a primary brain tumor and preventing the migratory spread of a primary brain tumor in a subject. These methods involve utilizing the CD24 surface protein selectively expressed on tumor progenitor cells as a therapeutic target as well as a means for directing oncolytic therapeutics directly to the tumor site. The present invention further relates to methods of diagnosing the presence of a brain tumor and monitoring the status of the brain tumor in a subject based on CD24 expression in tumor progenitor cells.

The invention discloses a method for inducing liver cell cells to be transformed into liver cancer stem cells. The method comprises the following steps: adding human liver cancer cells with a single cell state into a culture medium, so as to prepare a cell suspension solution; dropwise adding the cell suspension solution into a porous cellulose bracket; after enabling the cell suspension solution to permeate into the porous cellulose bracket, putting the porous cellulose bracket into a cell culture box and culturing and adhering; then adding the culture medium into the cell culture box and culturing for a plurality of days to obtain three-dimensional cultured cells; detecting changes of expression conditions of liver cancer stem cell marker molecules EpCAM (Epithelial Cellular Adhesion Molecule), OCT4, CD44 and CD133 in the three-dimensional cultured cells through utilizing Western Blot, quantitative PCR (Polymerase Chain Reaction), flow cytometry and IHC (Immunohistochemistry) and (or) a microscope is used for observing; the transformed liver cancer stem cells are detected. The invention further discloses the liver cancer stem cells and application of the liver cancer stem cells. The liver cancer stem cells disclosed by the invention have good drug resistance.

The invention provides a joint detection kit for multiple stem cell markers on surfaces of CTCs (circulating tumor cells) and an application of the kit. The joint detection kit for multiple stem cellmarkers on surfaces of CTCs comprises 1) a peripheral blood CTC enrichment reagent; 2) an RNA extraction reagent; 3) an RNA reverse transcription reagent; 4) a fluorescence labeled Taqman probe and aspecific primer; 5) a qPCR reaction system reagent and a hepatocellular carcinoma prediction formula. The kit can be used for biopsy of minimally invasive fluids of tumor patients, early diagnosis andearly warning of tumor metastasis and relapse are realized, the anti-tumor therapy effect and the tumor progression condition are monitored, molecular subtyping based on CTCs and screening of specific sensitive drugs for the CTCs are realized, so that knowledge about tumor metastasis, relapse and drug resistance related mechanisms is improved, individualized medical treatment of tumor patients isguided, the overall survival of the tumor patients is significantly improved, and the kit has great clinical significance.

A set of markers for melanoma cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression CD271.

The invention provides establishment and application of a hepatocellular carcinoma cell line HCC-LY5. Specifically, the hepatocellular carcinoma cell line HCC-LY5 provided in the invention has stable traits, can be subcultured stably and repeatedly, and is applicable to established animal models of hepatocellular carcinoma, thus being an ideal cell line for the basic and preclinical phase application study of hepatocellular carcinoma. In addition, a very small part of the hepatocellular carcinoma cell line HCC-LY5 expresses hepatocellular carcinoma stem cell marker CD133. The invention also provides application of the cell line in establishing model animals, screening drugs, and other aspects.

The invention relates to purposes of icaritin in preparing medicaments for inhibiting liver cancer stem cells. Icaritin can inhibit liver cancer stem cells by inhibiting expressions of liver cancer stem cell markers. Accordingly, the invention provides a further research direction of liver cancer targeted therapy, and it is hopeful for fundamentally curing liver cancer by inhibiting liver cancer stem cells.

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

This invention generally relates to a design and method for developing novel anti-tumor / cancer drugs, vaccines and therapies, using microRNA (miRNA) and its shRNA homologues / derivatives. More particularly, the present invention relates to the use of a nucleic acid composition capable of expressing mir-302-like gene silencing effectors upon delivery into human cells and then silencing mir-302-targeted cell cycle regulators and oncogenes, resulting in an inhibitory effect on tumor / cancer cell growth and metastasis. Mir-302 is the most predominant miRNA found in human embryonic stem (hES) and induced pluripotent stem (iPS) cells, yet its function is unclear. The present invention establishes that in humans mir-302 concurrently suppressed both cyclin-E-CDK2 and cyclin-D-CDK4 / 6 pathways and eventually blocked over 70% of the G1-S transition. Simultaneously, mir-302 also silences BMI-1, a cancer stem cell marker, and subsequently promotes the tumor suppressor functions of p16Ink4a and p14 / p19Arf in inhibiting CDK4 / 6-mediated cell proliferation. Therefore, the present invention for the first time reveals the tumor suppressor function of mir-302 in humans. This novel finding advances the design and method for developing new cancer drugs, vaccines and therapies directed against multiple kinds of human tumors and cancers, in particular including, but not limited, malignant skin, prostate, breast and liver cancers as well as various tumors.

The invention discloses a stem cell spheroid induction culture solution and a stem cell spheroid culture method and belongs to cell culture solutions. The method comprises the steps of enabling cells cultured in an original culture solution to grow to reach 90% in fusion degree, using a mixed culture solution to culture the cells, performing primary anoxia culture in a carbon dioxide culture box until 90% of the cells die; enabling remaining adherent cells to be subjected to phosphate buffered saline (PBS) washing and be added into the original culture solution to continuously being cultured; after the cell density reaches 90%, replacing the original culture solution with the mixed culture solution again, performing secondary anoxia culture, and collecting suspended stem cell spheroids. Besides, the cells are induced in an in vitro environment to continuously generate plenty of stem cell spheroids, and the stem cell spheroids can express specific stem cell markers such as CD44, CD133, OCT3 / 4, Nanog, SOX-2 and ABCG2 which are normal or tumor stem cell markers.

The disclosure reports on the identification and isolation of adult mouse lateral ventricle subventricular zone (SVZ) neurosphere initiating cells (NICs) by flow cytometry on the basis of GlastmidEGFRhighPlexinB2highCD24− / lowO4 / PSA-NCAM− / lowTer-119 / CD45− markers (GEPCOT cells). These cells are highly mitotic and short-lived in vivo based on fate-mapping with Ascl1CreERT2 and Dlx1CreERT2. In contrast, pre-GEPCOT cells were quiescent, expressed higher Glast, and lower EGFR and PlexinB2. Pre-GEP-COT cells could not form neurospheres but expressed the stem cell markers Glast-CreERT, GFAP-CreERT2, Sox2CreERT2, and Gli1C-reERT2 and were long-lived in vivo. While GEPCOT NICs were ablated by temozolomide, pre-GEPCOT cells survived and repopulated the SVZ. Conditional deletion of the Bmi-1 polycomb protein depleted pre-GEPCOT and GEPCOT cells, though pre-GEPCOT cells were more dependent upon Bmi-1 for p16Ink4a repression. These data distinguish quiescent NSCs from NICs and make it possible to study their properties in vivo.

The invention provides an isolated culture method of hair follicle stem cells of Yangtze River delta white goat. By adoption of the method, an isolated cell line has a good growth and division state,and relatively pure hair follicle stem cells can be obtained and are of a typical paving stone shape; primary cells grow fast, so that aggregated growth of cells can be observed on the third day, morecell aggregates in aggregated growing can be observed on the fourth day, the cells can overgrow 60 to 70 percent of a culture dish on the fifth day, and the positive rate of hair follicle stem cell markers is up to 90 percent or above. Results of cell chromosome analysis, hair follicle stem cell marker detection, cell activity detection and the like show that a built hair follicle stem cell lineof the Yangtze River delta white goat is high in activity, and the hair follicle stem cell markers are high in positive rate; and a good practical model can be provided for researching gene expressionand passageway regulation of skin cells and growth and a mechanisms of skin appendages, in particular for researching a mutual action mechanism among main cells of the skin.